Xenon Pharmaceuticals Expands Leadership on its Board of Directors with Appointments of Gillian M. Cannon and Justin Gover
09 8월 2023 - 5:01AM
Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused
biopharmaceutical company, today announced two new appointments to
its Board of Directors: Dr. Gillian M. Cannon and Mr. Justin Gover.
Dr. Cannon has more than 30 years of experience in the
pharmaceutical industry, where she served in business and
commercial leadership roles at Merck and Co., UCB, Otsuka and
Roivant. Mr. Gover served as founding Chief Executive Officer and
as a director of GW Pharmaceuticals from inception in 1999 until
its sale to Jazz Pharmaceuticals for $7.2 billion in May 2021 and
brings nearly twenty-five years of experience in leadership
positions in the biotechnology industry with a focus on epilepsy.
Mr. Ian Mortimer, Xenon’s President and Chief Executive Officer,
stated, “On behalf of our Board of Directors, I am delighted to
welcome Gillian and Justin to our Board. Gillian brings a vast
knowledge of commercializing novel medicines and leading successful
neuroscience franchises at large pharmaceutical companies. In
addition to his leadership acumen in the biotechnology industry,
Justin brings a depth of understanding of the epilepsy space, with
his background as founding CEO at GW Pharma and ongoing advocacy
efforts at organizations such as CURE Epilepsy. These Board
appointments are particularly timely given our continued efforts in
advancing XEN1101 in multiple Phase 3 epilepsy trials and our
preparation for commercialization as well as nearing a topline
readout of our XEN1101 Phase 2 X-NOVA clinical trial in major
depressive disorder. I am proud that both Gillian and Justin are
lending their expertise to Xenon and look forward to their valued
contributions and counsel.”
Gillian M. Cannon, Ph.D. brings more than 30 years of experience
in the pharmaceutical industry, where she has served in leadership
roles at multiple prominent global pharmaceutical companies
including Merck and Co. Inc., UCB Inc. and Otsuka Pharmaceuticals.
Serving more than 25 years at Merck, Dr. Cannon held a variety of
senior positions, including Global Vice President for Commercial
Operations at Merck’s start-up biosimilar business, Merck
BioVentures; Business Unit Head for Merck’s specialty products
franchise, and Global Commercial Head of Merck’s neuroscience
franchise. More recently, Dr. Cannon was the President of North
American Operations for UCB Inc. from 2015 to 2017. In 2018, Dr.
Cannon joined Roivant Sciences, a biotechnology company, serving
initially as COO for Alyvant and subsequently as Head of Commercial
Innovation for Roivant. Dr. Cannon currently serves on the Board of
Directors for Corcept Therapeutics, a publicly traded
clinical-stage biopharmaceutical company; Affibody AB, a Swedish
biotechnology company; Edinburgh Innovations, the commercial arm of
Edinburgh University; and Our Future Health Trading Board, the
largest UK health research program. She also serves as a lecturer
in the Drug Discovery Master’s program at Drexel University, PA.
Dr. Cannon received her B.Sc. from the University of Edinburgh and
Ph.D. in Health Administration from Temple University.
Justin Gover brings nearly twenty-five years of experience in
leadership positions in the biotechnology industry in the UK and
the U.S. Mr. Gover served as founding Chief Executive Officer and
as a director of GW Pharmaceuticals plc from the company’s
inception in 1999 until its sale to Jazz Pharmaceuticals plc for
$7.2 billion in May 2021. Mr. Gover led GW from London, UK from
1999 to 2015, at which time he relocated to San Diego, CA to open
the company’s US headquarters. At GW, Mr. Gover led the development
and commercialization of Epidiolex® (cannabidiol), which is
approved in the U.S. and Europe in the field of childhood onset
epilepsy. From 2018 to 2021, Mr. Gover served on the Board of
Directors of the Biotechnology Innovation Organization (BIO). Mr.
Gover currently serves on the Board of Directors for CURE Epilepsy
and Rady Children’s Institute for Genomic Medicine. Mr. Gover holds
an M.B.A. from the INSEAD business school in France and a B.Sc.
(Hons) from Bristol University, UK.
About Xenon Pharmaceuticals
Inc.
Xenon Pharmaceuticals (NASDAQ:XENE) is a
clinical stage biopharmaceutical company committed to developing
innovative therapeutics to improve the lives of patients with
neurological disorders. We are advancing a novel product pipeline
of neurology therapies to address areas of high unmet medical need,
with a focus on epilepsy. For more information, please visit
www.xenon-pharma.com.
Safe Harbor Statement
This press release contains forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and the Private Securities Litigation Reform
Act of 1995 and Canadian securities laws. These forward-looking
statements are not based on historical fact, and include statements
regarding our management and directors and their contributions and
our prospects; the potential efficacy, safety profile, future
development plans, addressable market, regulatory success and
commercial potential of our and our partners’ product candidates;
our ability to successfully develop and achieve milestones in our
XEN1101 and other development programs; our ability to successfully
develop and obtain regulatory approval of XEN1101 and our other
product candidates; and anticipated enrollment in our clinical
trials and the timing thereof. These forward-looking statements are
based on current assumptions that involve risks, uncertainties and
other factors that may cause the actual results, events, or
developments to be materially different from those expressed or
implied by such forward-looking statements. These risks and
uncertainties, many of which are beyond our control, include, but
are not limited to: clinical trials may not demonstrate safety and
efficacy of any of our or our collaborators’ product candidates;
promising results from pre-clinical development activities or early
clinical trial results may not be replicated in later clinical
trials; our ongoing discovery and pre-clinical efforts may not
yield additional product candidates; any of our or our
collaborators’ product candidates, including XEN1101, may fail in
development, may not receive required regulatory approvals, or may
be delayed to a point where they are not commercially viable; we
may not achieve additional milestones in our proprietary or
partnered programs; regulatory agencies may impose additional
requirements or delay the initiation of clinical trials; the impact
of competition; the impact of expanded product development and
clinical activities on operating expenses; the impact of new or
changing laws and regulations; the impact of pandemics and other
health crises on our research and clinical development plans and
timelines and results of operations, including impact on our
clinical trial sites, collaborators, regulatory agencies and
related review times, and contractors who act for or on our behalf;
the impact of unstable economic conditions in the general domestic
and global economic markets; adverse conditions from geopolitical
events; as well as the other risks identified in our filings with
the Securities and Exchange Commission and the securities
commissions in British Columbia, Alberta, and Ontario. These
forward-looking statements speak only as of the date hereof and we
assume no obligation to update these forward-looking statements,
and readers are cautioned not to place undue reliance on such
forward-looking statements.
“Xenon” and the Xenon logo are registered
trademarks or trademarks of Xenon Pharmaceuticals Inc. in various
jurisdictions. All other trademarks belong to their respective
owner.
Investor/Media Contact:Jodi RegtsXenon
Pharmaceuticals Inc.Phone: 604.484.3353Email:
investors@xenon-pharma.com
Xenon Pharmaceuticals (NASDAQ:XENE)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Xenon Pharmaceuticals (NASDAQ:XENE)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024